Johnson & Johnson (NYSE: JNJ) continues to hold its status as one of Wall Street's most reliable Dividend Kings in 2026, having raised its dividend for more than 60 consecutive years. The healthcare giant completed its separation from its consumer health division — now operating independently as Kenvue — in 2023, allowing J&J to sharpen its focus on its two core segments: Innovative Medicine (pharmaceuticals) and MedTech.
Following the Kenvue spin-off, J&J has repositioned itself as a pure-play healthcare innovator. Its Innovative Medicine segment, which includes blockbuster drugs such as Darzalex (daratumumab) for multiple myeloma and Tremfya (guselkumab) for inflammatory diseases, has been a key revenue driver. The MedTech segment, meanwhile, covers surgical robotics, orthopedics, and cardiovascular devices, areas where J&J has pursued strategic acquisitions to bolster its pipeline.
For fiscal year 2024, Johnson & Johnson reported total sales of approximately $88.8 billion, reflecting continued growth across both segments. The company has maintained a strong balance sheet with a coveted AAA credit rating from Standard & Poor's — one of only a handful of U.S. corporations to hold this distinction — which underpins its capacity to sustain and grow its dividend over time.
J&J's dividend yield has hovered in the 3% range in early 2026, making it an attractive option for income-focused investors in a volatile market environment. The company has also signaled continued investment in oncology, immunology, and neuroscience through both internal R&D and bolt-on acquisitions, suggesting a long-term growth runway even as some key drug patents face future expiration pressures.
Analysts note that while J&J faces ongoing litigation related to its talc-based products — with the company pursuing a bankruptcy settlement strategy through its subsidiary — the core business fundamentals remain robust. For dividend-focused investors seeking stability and consistent income in 2026, Johnson & Johnson's combination of financial strength, diversified healthcare exposure, and decades-long dividend track record keeps it among the most discussed blue-chip holdings.
